Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving Average – Here’s Why

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.80 and traded as high as $4.52. Oramed Pharmaceuticals shares last traded at $4.32, with a volume of 162,435 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, Oramed Pharmaceuticals currently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Stock Performance

The company has a market cap of $178.88 million, a P/E ratio of 1.66 and a beta of 1.22. The stock has a 50 day moving average price of $4.11 and a 200 day moving average price of $3.81.

Insider Transactions at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total value of $611,020.00. Following the sale, the chief operating officer directly owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Avraham Gabay sold 73,360 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the sale, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at $3,029,750.35. The trade was a 9.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 17.80% of the stock is owned by insiders.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in Oramed Pharmaceuticals by 2.7% during the 1st quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after purchasing an additional 3,909 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 7,738 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 14,297 shares in the last quarter. Kathmere Capital Management LLC purchased a new stake in shares of Oramed Pharmaceuticals in the first quarter valued at $51,000. Finally, Jane Street Group LLC boosted its position in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after buying an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.